- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00256646
Markers and Mechanisms of Vascular Disease in Type II Diabetes
CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes
OBJECTIVES: Vascular Disease is the leading cause of complications and death in patients with diabetes. Risk markers and underlying mechanisms have not been fully elucidated, and may differ from those in non-diabetic individuals. The unifying theme for the Program Project is that hyperglycemia and insulin resistance alter a number of biological processes which interact in vicious cycles to accelerate atherogenesis and are consequently major underlying risk factors for vascular disease. The overall objectives are to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.
RESEARCH PLAN: Over the past 4 years, we have collaborated with the DCCT/EDIC Study Group, and have made novel observations regarding vascular disease pathogenesis in Type 1 Diabetes. This work has focused our studies on specific pathogenic processes. We will now study a Type 2 Diabetes cohort from the VA Cooperative Study, "Glycemic Control and the Complications of Diabetes, Type 2", with high vascular disease event rates. These collaborations provide a unique opportunity to address the pathogenesis of accelerated atherogenesis in the two main types of diabetes, and will greatly augment the scientific knowledge that will be gained in the conduct of these world-class prospective trials.
METHODS: The Program Project has 4 projects and 3 cores. Project 1 will assess lipoproteins, glycoxidative stress, and inflammation as risk factors in studies involving Type 2 Diabetes patients and cultured cell systems. Based on preliminary data from our initial studies Type 1 patients, changes in the NMR lipoprotein subclass profile will be emphasized.
Project 2 will elucidate interactions between inflammation, modifications of lipoproteins, and autoimmunity in vascular disease risk. These novel concepts are also based upon exciting preliminary data pertaining to LDL-antibody complexes.
Project 3 will pursue interesting preliminary data and define the role of the kallikrein-kinin system in vascular disease complications, with effects on mitogenesis and matrix production.
Project 4 will assess the role of the Insulin Resistance Syndrome and novel factors secreted from adipocytes in the pathophysiology of biochemical risk factors and cardiovascular complications.
Cores include an Administrative Core, a Biostatistics and Epidemiology Core which will link with the trials data coordinating centers, and Molecular and Statistical Genetics Core. Investigators will work in close collaboration with the VA Executive Committee, Study Centers, the Hines Coordinating Center, and some of the other ancillary studies. All data analysis involving clinical outcomes will be performed at the Hines Coordinating Center.
There is true synergism among the projects at both scientific and logistical levels. The Program Project design allows for interactions among multidisciplinary investigators studying the same cohort, which will define how multiple pathological processes interact at the level of the arterial wall to promote atherosclerosis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Primary Hypothesis:
Secondary Hypotheses:
Primary Outcomes:
Study Abstract:
OBJECTIVES: Vascular Disease is the leading cause of complications and death in patients with diabetes. Risk markers and underlying mechanisms have not been fully elucidated, and may differ from those in non-diabetic individuals. The unifying theme for the Program Project is that hyperglycemia and insulin resistance alter a number of biological processes which interact in vicious cycles to accelerate atherogenesis and are consequently major underlying risk factors for vascular disease. The overall objectives are to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.
RESEARCH PLAN: Over the past 4 years, we have collaborated with the DCCT/EDIC Study Group, and have made novel observations regarding vascular disease pathogenesis in Type 1 Diabetes. This work has focused our studies on specific pathogenic processes. We will now study a Type 2 Diabetes cohort from the VA Cooperative Study, "Glycemic Control and the Complications of Diabetes, Type 2", with high vascular disease event rates. These collaborations provide a unique opportunity to address the pathogenesis of accelerated atherogenesis in the two main types of diabetes, and will greatly augment the scientific knowledge that will be gained in the conduct of these world-class prospective trials.
METHODS: The Program Project has 4 projects and 3 cores. Project 1 will assess lipoproteins, glycoxidative stress, and inflammation as risk factors in studies involving Type 2 Diabetes patients and cultured cell systems. Based on preliminary data from our initial studies Type 1 patients, changes in the NMR lipoprotein subclass profile will be emphasized.
Project 2 will elucidate interactions between inflammation, modifications of lipoproteins, and autoimmunity in vascular disease risk. These novel concepts are also based upon exciting preliminary data pertaining to LDL-antibody complexes.
Project 3 will pursue interesting preliminary data and define the role of the kallikrein-kinin system in vascular disease complications, with effects on mitogenesis and matrix production.
Project 4 will assess the role of the Insulin Resistance Syndrome and novel factors secreted from adipocytes in the pathophysiology of biochemical risk factors and cardiovascular complications.
Cores include an Administrative Core, a Biostatistics and Epidemiology Core which will link with the trials data coordinating centers, and Molecular and Statistical Genetics Core. Investigators will work in close collaboration with the VA Executive Committee, Study Centers, the Hines Coordinating Center, and some of the other ancillary studies. All data analysis involving clinical outcomes will be performed at the Hines Coordinating Center.
There is true synergism among the projects at both scientific and logistical levels. The Program Project design allows for interactions among multidisciplinary investigators studying the same cohort, which will define how multiple pathological processes interact at the level of the arterial wall to promote atherosclerosis.
Main Manuscript:
There is no independent data for this study, it was part of a larger study. Therefore there will be no results for this record/study.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85012
- Carl T. Hayden VA Medical Center
-
Tucson, Arizona, Forente stater, 85723
- Southern Arizona VA Health Care System, Tucson
-
-
California
-
Fresno, California, Forente stater, 93703
- VA Central California Health Care System, Fresno
-
Long Beach, California, Forente stater, 90822
- VA Medical Center, Long Beach
-
San Diego, California, Forente stater, 92161
- VA San Diego Healthcare System, San Diego
-
-
Florida
-
Miami, Florida, Forente stater, 33125
- Miami VA Healthcare System, Miami, FL
-
-
Illinois
-
Hines, Illinois, Forente stater, 60141-5000
- Edward Hines, Jr. VA Hospital
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202-2884
- Richard Roudebush VA Medical Center, Indianapolis
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40502
- VA Medical Center, Lexington
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55417
- VA Medical Center, Minneapolis
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68105-1873
- VA Medical Center, Omaha
-
-
New Jersey
-
East Orange, New Jersey, Forente stater, 07018
- VA New Jersey Health Care System, East Orange
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15240
- VA Pittsburgh Health Care System
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Michael E. DeBakey VA Medical Center (152)
-
San Antonio, Texas, Forente stater, 78229
- VA South Texas Health Care System, San Antonio
-
-
Virginia
-
Salem, Virginia, Forente stater, 24153
- VA Medical Center, Salem VA
-
-
-
-
-
San Juan, Puerto Rico, 00921
- VA Medical Center, San Juan
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents
Exclusion Criteria:
Patients that did not participate in the VADT.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Group 1
Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2".
|
ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes.
It helps to control blood sugar.
Treatment is combined with diet and exercise.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The primary outcome measure is to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.
Tidsramme: 2, 4, and 6 years.
|
2, 4, and 6 years.
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Carlos Abraira, MD, Miami VA Healthcare System, Miami, FL
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T; VADT Investigators. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct;224(2):526-31. doi: 10.1016/j.atherosclerosis.2012.08.006. Epub 2012 Aug 21.
- Bhensdadia NM, Hunt KJ, Lopes-Virella MF, Michael Tucker J, Mataria MR, Alge JL, Neely BA, Janech MG, Arthur JM; Veterans Affairs Diabetes Trial (VADT) study group. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney Int. 2013 Jun;83(6):1136-43. doi: 10.1038/ki.2013.57. Epub 2013 Mar 27.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 465D
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes mellitus
-
University Hospital Inselspital, BerneFullført
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Fullført
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Har ikke rekruttert ennåT2DM (type 2 diabetes mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (type 2 diabetes mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiFullført
-
Haisco Pharmaceutical Group Co., Ltd.Fullført
-
PegBio Co., Ltd.FullførtType 2 diabetes mellitus (T2DM)Kina
Kliniske studier på Rosiglitazone
-
GlaxoSmithKlineFullførtDiabetes mellitus, type 2
-
GlaxoSmithKlineFullførtDiabetes mellitus, type 2
-
GlaxoSmithKlineFullførtNevropati, diabetikerNederland
-
Medstar Health Research InstituteGlaxoSmithKlineAvsluttet
-
Baskent UniversityFullførtOvervekt | Type 2 diabetes mellitusTyrkia
-
Hospital Authority, Hong KongUkjentKardiovaskulære sykdommer | Nyresykdommer | Kronisk sykdomKina
-
GlaxoSmithKlineFullførtAlzheimers sykdomForente stater, Australia, Spania, Bulgaria, Polen, Tyskland, Filippinene, Singapore, Belgia, Canada, Hong Kong, Korea, Republikken, Finland, Slovenia, Tsjekkia, Frankrike, Sør-Afrika, Sverige, Nederland, Malaysia, Storbritannia, Sl...
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Fullført
-
Jonsson Comprehensive Cancer CenterNational Institutes of Health (NIH)AvsluttetSvulster i hjernen og sentralnervesystemetForente stater
-
GlaxoSmithKlineAvsluttetAlzheimers sykdomAustralia, Spania, Forente stater, Bulgaria, Tyskland, Belgia, Canada, Hong Kong, Korea, Republikken, Portugal, Argentina, Chile, Hellas, Slovenia, Tsjekkia, Frankrike, Ungarn, Italia, Sør-Afrika, India, Sverige, Nederland, Filippinene, Pole... og mer